I dig around and found this old post on HC from 2008. https://hotcopper.com.au/threads/osiris-vs-mesoblast-mesenchymal-stem-cells.791600/ The post outline the difference between MSC from Osiris and MSB. From my understanding, they are different. Therefore the objection based on Osiris' trial failure should be irrelevant. Any thoughts?
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-164
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.26 |
Change
-0.155(6.43%) |
Mkt cap ! $2.841B | |||
| Open | High | Low | Value | Volume |
| $2.33 | $2.35 | $2.15 | $14.62M | 6.487M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 12623 | $2.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.26 | 17522 | 14 |
View Market Depth
| Last trade - 11.18am 21/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |